Send to

Choose Destination
Expert Rev Anticancer Ther. 2009 Apr;9(4):511-23. doi: 10.1586/era.09.7.

Novel therapeutic agents for osteosarcoma.

Author information

Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd floor, Bronx, NY 10467, USA.


Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center